Home Cart Sign in  
Chemical Structure| 302962-49-8 Chemical Structure| 302962-49-8

Structure of Dasatinib
CAS No.: 302962-49-8

Chemical Structure| 302962-49-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Dasatinib is a potent and dual Abl/ Src inhibitor IC50 of < 1 nM/0.8 nM respectively and also inhibits c-Kit (WT)/c-Kit (D816V) with IC50 of 79 nM/37 nM.

Synonyms: BMS-354825; Sprycel

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations      Show More

Fofie, Christian Kuete ; Granja-Vazquez, Rafael ; Truong, Vincent ; Walsh, Patrick ; Price, Theodore ; Biswas, Swati , et al.

Abstract: Chronic pain is a global health issue, yet effective treatments remain limited due to poor preclinical-to-human translation. To address this, we developed a high-content screening (HCS) platform using hiPSC-derived nociceptors to identify analgesics targeting the peripheral nervous system. These cells, cultured on multi-well microelectrode arrays, achieved nearly 100% active electrodes by week 2, maintaining stable activity for at least 2 weeks. After 28 days, we assessed drug effects on neuronal activity, achieving strong assay performance (robust Z′ > 0.5). Pharmacological tests confirmed responses to key analgesic targets, including ion channels (Nav, Cav, Kv, and TRPV1), receptors (AMPAR and GABA-R), and kinase inhibitors (tyrosine and JAK1/2). Transcriptomic analysis validated target expression, though levels differed from primary human DRG cells. The platform was used to screen over 700 natural compounds, demonstrating its potential for analgesic discovery. This HCS platform facilitates the rapid discovery of uncharacterized analgesics, reducing preclinical-to-human translation failure.

Purchased from AmBeed: ; ; ;

Leclercq, Gabrielle ; Haegel, Hélène ; Toso, Alberto ; Zimmermann, Tina ; Green, Luke ; Steinhoff, Nathalie , et al.

Abstract: Background: T cell engaging therapies, like chimeric antigen receptor T cells and T cell bispecific antibodies (TCBs), efficiently redirect T cells towards tumor cells, facilitating the formation of a cytotoxic synapse and resulting in subsequent tumor cell killing, a process that is accompanied by the release of cytokines. Despite their promising efficacy in the clinic, treatment with TCBs is associated with a risk of cytokine release syndrome (CRS). The aim of this study was to identify small molecules able to mitigate cytokine release while retaining T cell-mediated tumor killing. Methods: By screening a library of 52 Food and Drug Administration approved kinase inhibitors for their impact on T cell proliferation and cytokine release after CD3 stimulation, we identified mTOR, JAK and Src kinases inhibitors as potential candidates to modulate TCB-mediated cytokine release at pharmacologically active doses. Using an in vitro model of target cell killing by human peripheral blood mononuclear cells, we assessed the effects of mTOR, JAK and Src kinase inhibitors combined with 2+1 T cell bispecific antibodies (TCBs) including CEA-TCB and CD19-TCB on T cell activation, proliferation and target cell killing measured by flow cytometry and cytokine release measured by Luminex. The combination of mTOR, JAK and Src kinase inhibitors together with CD19-TCB was evaluated in vivo in non-tumor bearing stem cell humanized NSG mice in terms of B cell depletion and in a lymphoma patient-derived xenograft (PDX) model in humanized NSG mice in terms of antitumor efficacy. Results: The effect of Src inhibitors differed from those of mTOR and JAK inhibitors with the suppression of CD19-TCB-induced tumor cell lysis in vitro, whereas mTOR and JAK inhibitors primarily affected TCB-mediated cytokine release. Importantly, we confirmed in vivo that Src, JAK and mTOR inhibitors strongly reduced CD19-TCB-induced cytokine release. In humanized NSG mice, continuous treatment with a Src inhibitor prevented CD19-TCB-mediated B cell depletion in contrast to mTOR and JAK inhibitors, which retained CD19-TCB efficacy. Ultimately, transient treatment with Src, mTOR and JAK inhibitors minimally interfered with antitumor efficacy in a lymphoma PDX model. Conclusions: Taken together, these data support further evaluation of the use of Src, JAK and mTOR inhibitors as prophylactic treatment to prevent occurrence of CRS.

Purchased from AmBeed: ; ; ; ;

Fouad S. Moghrabi ; Aktham Aburub ; Hala M. Fadda ;

Abstract: Purpose: pH-dependent drug-drug interactions (DDIs) with poorly soluble, weakly basic drugs may lead to clinical implications. Dasatinib is a tyrosine kinase inhibitor with reduced absorption in patients on acid-reducing agents (ARAs). The objective of this study is to investigate the influence of gastric pH on dasatinib supersaturation and determine if vitamin C (L-ascorbic acid) can improve dasatinib concentrations under simulated hypochlorhydric gastric conditions. Methods: A dynamic, in vitro, multi-compartment, simulated stomach duodenum (SSD) model mimicking fluid volumes and transfer rates was used to investigate the concentration of BCS class IIb drugs versus time curves. Dasatinib and lamotrigine were explored under normal, fasted, simulated gastric fluids (pH 2) (FaSGF), hypochlorhydric simulated gastric fluids (pH 4.5) (FaSGFhypo) and FaSGFhypo with 1000 mg of vitamin C. Results: Significant supersaturation of dasatinib was observed in the duodenum compartment of the SSD model in FaSGF. A 90% reduction in dasatinib AUC∞ was observed in FaSGFhypo. Upon addition of vitamin C to FaSGFhypo, drug concentrations were restored to those observed in FaSGF. Lamotrigine AUC∞ in the duodenal compartment were similar in both FaSGF and FaSGFhypo. The in vitro trends observed for dasatinib and lamotrigine are reflective of the trends observed in vivo in subjects receiving treatment with ARAs. Conclusions: The SSD model serves as a good in vitro tool for assessing the effect of pH-dependent DDIs on bioavailability of weakly basic drugs with solubility/ dissolution limited absorption. Vitamin C provides a promising approach for improving bioavailability of poorly soluble, weakly basic drugs in hypochlorhydric patients.

Keywords: Dissolution ; Ionization ; In vitro in vivo correlations ; Proton pump inhibitors ; Oral drug delivery

Purchased from AmBeed: ;

Leclercq, Gabrielle ;

Abstract: T cell bispecific antibodies (TCBs) are a novel class of T cell engagers redirecting T cells towards tumor cells, facilitating the formation of a cytotoxic synapse and resulting in tumor celllysis. On-target activity of TCBs may come with a risk of Cytokine Release Syndrome (CRS), characterized by elevated levels of pro-inflammatory cytokines in the serum, such as IL-6, IL-1β, TNF-α or IFN-γ and over activation of immune cells. Besides, the expression of the tumorassociated antigen on healthy cells may induce off-tumor activity of the TCB and contribute to inflammation. Despite the use of step-up dosing, glucocorticoids, or tocilizumab to manage or prevent these safety liabilities, they remain the major dose-limiting toxicities associated with the treatment of T cell engagers, highlighting the need to develop preventive mitigation treatments. To this aim, we investigated the biological mechanisms and the chronology of events involved in TCB-mediated cytokine release and explored mitigation strategies that might retain profound treatment efficacy while reducing cytokine release. Using an in vitro co-culture of peripheral blood mononuclear cells (PBMCs) or total leukocytes(PBMCs + neutrophils) and target cells with the respective TCBs, or whole blood treated with a B cell depleting TCB, we confirmed the contribution of T cell and myeloid cells and revealed the role of neutrophils in the TCB-mediated cytokine release. In the same model, the use of anticytokine neutralizing antibodies provided insights into the chronology of events triggering the cascade of cytokines after TCB stimulation. Ultimately this work guided the evaluation of mitigation strategies directed against T-cell derived cytokine release by targeting kinases involved in signaling pathways downstream of the T cell receptor (TCR) after stimulation with TCBs. A novel small molecule-kinase inhibitors screen identified mTOR, JAK and Src inhibitors as candidates to switch-off T-cell derived cytokine release. We validated the effects of these kinase inhibitors and fine-tuned their effective doses in in vitro co-cultures of peripheral blood mononuclear cells (PBMCs) and tumor cells with the respective TCBs. In vivo, we used nontumor or tumor-bearing-humanized NSG mice to assess the effect of mTOR, JAK and Srcinhibitors on CD19-TCB-mediated cytokine release and anti-tumor efficacy. Altogether, we confirmed the biological mechanisms of the TCB-mediated cytokine cascade and revealed the contribution of neutrophils. Our work on kinase inhibitors highlights their differential activities on the inhibition of cytokine release and/or T cell cytotoxicity and demonstrates the decoupling between both mechanisms. Our data open new horizons for the prophylactic mitigation of CRS with the use of FDA approved mTOR and JAK inhibitors or the transient use of the Src inhibitor dasatinib. Finally, our results also indicate that dasatinib may serve as an “antidote” against adverse events related to the treatment with TCBs such as high grade CRS or unpredictable off-tumor activity of TCBs, a strategy which is now implemented the clinic.

Purchased from AmBeed: ; ; ; ;

Alternative Products

Product Details of Dasatinib

CAS No. :302962-49-8
Formula : C22H26ClN7O2S
M.W : 488.01
SMILES Code : O=C(C1=CN=C(NC2=NC(C)=NC(N3CCN(CCO)CC3)=C2)S1)NC4=C(C)C=CC=C4Cl
Synonyms :
BMS-354825; Sprycel
MDL No. :MFCD11046566
InChI Key :ZBNZXTGUTAYRHI-UHFFFAOYSA-N
Pubchem ID :3062316

Safety of Dasatinib

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H318-H336-H373-H410
Precautionary Statements:P260-P264-P270-P271-P273-P280-P301+P312+P330-P304+P340+P312-P305+P351+P338+P310-P314-P391-P403+P233-P405
Class:9
UN#:3077
Packing Group:

Related Pathways of Dasatinib

RTK

Isoform Comparison

Biological Activity

Target
  • c-Kit

    c-Kit (wt), IC50:79 nM

    c-Kit (D816V), IC50:37 nM

  • Src

    Src, IC50:0.8 nM

  • Abl

    Abl, IC50:0.6 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
REH GCR cells 100 nM 48 h Dasatinib was the only inhibitor able to reduce the number of cells in this population when combined with dexamethasone, indicating its effectiveness in inhibiting active signaling in GC-resistant cells. Nat Commun. 2023 May 22;14(1):2935.
NALM6 cells 100 nM 48 h The combination of dexamethasone and dasatinib resulted in more apoptosis compared to treatment with dexamethasone or dasatinib alone in a dose-dependent manner, indicating its effectiveness in targeting active signaling in GC-resistant cells. Nat Commun. 2023 May 22;14(1):2935.
A375 cells 100 nM 24 h To assess the inhibitory effect of dasatinib on TCB-mediated target-cell killing, results showed that 100 nM dasatinib significantly inhibited target-cell killing J Immunother Cancer. 2021 Jul;9(7):e002582.
SKM-1 cells 100 nM 24 h To assess the inhibitory effect of dasatinib on TCB-mediated target-cell killing, results showed that 100 nM dasatinib significantly inhibited target-cell killing J Immunother Cancer. 2021 Jul;9(7):e002582.
PS125 3, 10 nM 1–24 h Dasatinib significantly reduced cell viability and induced G2/M phase cell cycle arrest. Cancer Lett. 2014 Nov 1;354(1):68-76.
D556 1, 5, 10, 50, 100 nM 1–24 h Dasatinib significantly reduced cell viability and induced G2/M phase cell cycle arrest. Cancer Lett. 2014 Nov 1;354(1):68-76.
DAOY 1, 5, 10, 50, 100 nM 1–24 h Dasatinib significantly reduced cell viability and induced G2/M phase cell cycle arrest. Cancer Lett. 2014 Nov 1;354(1):68-76.
A375 cells 100 nM 24 h To assess the inhibitory effect of dasatinib on TCB-mediated target-cell killing, results showed that 100 nM Dasatinib significantly inhibited target-cell killing. J Immunother Cancer. 2021 Jul;9(7):e002582.
SKM-1 cells 100 nM 24 h To assess the inhibitory effect of dasatinib on TCB-mediated target-cell killing, results showed that 100 nM Dasatinib significantly inhibited target-cell killing. J Immunother Cancer. 2021 Jul;9(7):e002582.
Human bone marrow mesenchymal stem cells (BM-MSCs) 1 μM 21 days Dasatinib inhibited the viability and adipogenesis commitment of human BM-MSCs, reducing adipocyte formation. Cardiovasc Diabetol. 2023 Aug 17;22(1):214.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice PC3/CD63-Antares2 xenograft model Intraperitoneal injection 5 mg/kg Once every 3 days for 35 days Evaluated dasatinib's inhibitory effect on tumor-derived exosome secretion, found low-dose dasatinib significantly reduced luminescence signals in blood and exosome-homing organs Sci Rep. 2020 Oct 6;10(1):16616
Mice NALM6-Luc+ xenograft model Oral 35 mg/kg Twice daily for 14 days Combination treatment resulted in a significant reduction of engraftment compared to vehicle, dexamethasone or dasatinib alone and increased survival, indicating its ability to overcome GC resistance. Nat Commun. 2023 May 22;14(1):2935.
NSG mice Humanized NSG mice Oral 50 mg/kg Twice daily for 2 days To assess the inhibitory effect of dasatinib on CD19-TCB-mediated B cell depletion and cytokine release, results showed that dasatinib significantly inhibited B cell depletion and cytokine release J Immunother Cancer. 2021 Jul;9(7):e002582.
Mice PS125 mouse MB model Oral 15 mg/kg Daily for 4 weeks Dasatinib treatment significantly reduced tumor volume with no observed toxicity. Cancer Lett. 2014 Nov 1;354(1):68-76.
NSG mice Humanized NSG mice Oral 50 mg/kg Twice daily for 2 days To evaluate the inhibitory effect of Dasatinib on CD19-TCB-mediated B cell depletion and cytokine release in vivo, results showed that Dasatinib significantly inhibited B cell depletion and cytokine release. J Immunother Cancer. 2021 Jul;9(7):e002582.
Mice Dbb mice (obese, type 2 diabetic model) Oral gavage 5 mg/kg Once per week for four weeks Dasatinib reduced lipid accumulation in the heart and bone marrow of diabetic mice, improved diastolic function, and reduced cardiac fibrosis. Cardiovasc Diabetol. 2023 Aug 17;22(1):214.

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03573596 CML, Relapsed PHASE2 UNKNOWN 2024-02-01 Aarhus University Hospital, Aa... More >>rhus, Denmark|Odense University Hospital, Odense, Denmark|Helsinki University Hospital, Helsinki, Finland|Centre Hospitalo-Universitaire, Créteil, France|University Hospital, Bonn, Germany|VU University medical center, Amsterdam, 1081HV, Netherlands|Albert Schweitzer Hospital, Dordrecht, Netherlands|Radboud University medical center, Nijmegen, Netherlands|Erasmus University medical center, Rotterdam, Netherlands|Haukeland, Bergen University Hospital, Bergen, Norway|Oslo University Hospital, Oslo, Norway|Stavanger University Hospital, Stavanger, Norway|Troms? University Hospital, Troms?, Norway|St Olavs Hospital-Trondheim University Hospital, Trondheim, Norway|University Hospital, Link?ping, Sweden|Sunderby Sjukhus, Lule?, Sweden|Lund University Hospital, Lund, Sweden|Karolinska Hospital, Stockholm, Sweden|Ume? University Hospital, Ume?, Sweden|Uppsala University Hospital (Akademiska), Uppsala, Sweden|?rebro University Hospital, ?rebro, Sweden Less <<
NCT00454753 - NO_LONGER_AVAILABLE - -
NCT00099606 Neoplasms PHASE1 COMPLETED 2025-07-07 Local Institution, Boston, Mas... More >>sachusetts, United States|Local Institution, Detroit, Michigan, United States|Local Institution, Glasgow, Strathclyde, United Kingdom Less <<
NCT00787267 Non Small Cell Lung Cancer PHASE2 TERMINATED 2025-06-13 Durham VA Medical Center, Durh... More >>am, North Carolina, 27705, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States|Duke Raleigh, Raleigh, North Carolina, 27609, United States Less <<
NCT01627132 Chronic Myeloid Leukemia PHASE2 UNKNOWN 2025-01-19 Nippon Medical School, Sendagi... More >> 1-1-5, Bunkyo-ku,Tokyo, 113-8603, Japan Less <<
NCT00538980 Polycythemia Vera PHASE2 TERMINATED 2010-08-27 Emory Winship Cancer Institute... More >>, Atlanta, Georgia, 30322, United States|Hematology/Oncology Associates of Rockland, New City, New York, 10956, United States|Weill Cornell Medical College - New York Presbyterian Hospital, New York, New York, 10021, United States|The Jones Clinic, Germantown, Tennessee, 38138, United States Less <<
NCT00979160 Systemic Mastocytosis PHASE2 UNKNOWN 2025-12-12 Istituto di ematologia "L e A ... More >>Seragnoli" - Policlinico universitario Sant'Orsola-Malpighi, Bologna, 40138, Italy|Dipartimento di Ematologia - S.O.D. di Ematologia Università degli Studi di Firenze - Azienda Ospedaliera Careggi, Firenze, 50134, Italy|Divisione di Ematologia Ospedale Niguarda Ca' Grande, Milano, 20162, Italy|Divisione di Allergologia e Immunologia Clinica, Università Federico II, Napoli, 80131, Italy|Divisione di Ematologia Università di Torino Ospedale San Luigi Gonzaga, Orbassano (TO), 10043, Italy|Istituto di Ematologia Università degli Studi di Pavia - Policlinico S. Matteo IRCCS, Pavia, 27100, Italy|Unità di Ematologia e Trapianto Osseo CROB, Centro di Riferimento Oncologico di Basilicata +39 0972 726729 Fax +30 0972 726217 e-mail: p.musto@crob.it, Rionero in Vulture (Pz), Italy|Ematologia Tor Vergata University Hospital, Roma, 00133, Italy|Divisione di Ematologia Policlinico Universitario "Agostino Gemelli", Roma, 00168, Italy|Ematologia e Trapianti Università degli Studi di Siena - Policlinico S. Maria alle Scotte, Siena, 53100, Italy|Divisione di Ematologia e Trapianto Midollo Osseo Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia", Udine, 33100, Italy|Sezione di Ematologia - Dipartimento di Medicina Clinica e Sperimentale Policlinico G.B.Rossi - Università degli Studi di Verona, Verona, 37134, Italy Less <<
NCT00391989 Lymphoblastic Leukemia, Acute PHASE2 COMPLETED 2025-09-08 Ospedale Sant'Anna-17, Roncigl... More >>ione, Viterbo, Italy|Nuovo Ospedale "Torrette", Ancona, Italy|Ospedale San Donato USL 8, Arezzo, Italy|Presidio Ospedaliero "C. e G.Mazzoni", Ascoli Piceno, Italy|Università degli Studi di Bari, Bari, Italy|Ist.Ematologia e Oncologia Medica L.e A. Seragnoli, Bologna, Italy|Azienda Spedali Civili, Brescia, Italy|Osp. Reg. A. Di Summa, Brindisi, Italy|Servizio di Ematologia - CTMO - ASL 8 P.O. Binaghi, Cagliari, Italy|Università di Catania - Cattedra di Ematologia - Ospedale "Ferrarotto", Catania, Italy|Azienda Ospedaliera Pugliese Ciaccio, Catanzaro, Italy|Sez.Ematologia e Dip. scienze Biomediche Arcispedale S. Anna, Ferrara, Italy|Divisione Ematologia 1 - Azienda Ospedaliera Universitaria "San Martino", Genova, Italy|Ospedale Niguarda " Ca Granda", Milano, Italy|Sez. di medicina Interna Oncologia ed Ematologia, Modena, Italy|Azienda Ospedaliera di Rilievo Nazionale "A. Cardarelli" - Div. TERE, Napoli, Italy|Azienda Ospedaliera di Rilievo Nazionale "A. Cardarelli", Napoli, Italy|Ematologia Università Federico II, Napoli, Italy|Ospedale S. Luigi Gonzaga, Orbassano, Italy|Dip. Oncologico "La Maddalena", Palermo, Italy|Div. di Ematologia - A.O. "V. Cervello", Palermo, Italy|Università degli Studi di Palermo - A.U. Policlinico, Palermo, Italy|Div. di Ematologia IRCCS Policlinico S. Matteo, Pavia, Italy|U.O. Ematologia Clinica - Azienda USL di Pescara, Pescara, Italy|Istituto di Ematologia- Ospedale San Carlo, Potenza, Italy|Ospedale S.Maria delle Croci, Ravenna, Italy|Dipartimento Emato-Oncologia A.O."Bianchi-Melacrino-Morelli", Reggio Calabria, Italy|Ospedale S. Camillo, Rome, Italy|Ospedale S.Eugenio, Rome, Italy|Università Cattolica del Sacro Cuore, Rome, Italy|Università degli Studi di Roma "La Sapienza", Rome, Italy|Università degli Studi di Tor Vergata, Rome, Italy|Ospedale Casa Sollievo della sofferenza, San Giovanni Rotondo, Italy|Serv. di Ematologia Ist. di Ematologia ed Endocrinologia, Sassari, Italy|Policlinico Universitario, Udine, Italy|Policlinico G.B. Rossi, Verona, Italy Less <<
NCT05024357 Precursor Cell Lymphoblastic L... More >>eukemia-Lymphoma|Philadelphia-Positive Acute Lymphoblastic Leukemia|ALL, Adult Less << UNKNOWN 2023-06-30 First Affiliated Hospital of X... More >>ian Jiaotong University, Xi'an, Shaanxi, 710061, China Less <<
NCT02389972 Leukemia, Myelogenous, Chronic... More >>, BCR-ABL Positive Less << COMPLETED 2017-07-13 Local Institution, Wuhan, Hube... More >>i, 430022, China Less <<
NCT00529763 Leukemia PHASE2 COMPLETED 2022-04-20 Local Institution, Beijing, Be... More >>ijing, 100044, China|Local Institution - 0004, Fuzhou, Fujian, 350001, China|Local Institution, Fuzhou, Fujian, 350001, China|Local Institution, Guangzhou, Guangdong, 510515, China|Local Institution, Nanjing, Jiangsu, 210029, China|Local Institution - 0008, Suzhou, Jiangsu, 215006, China|Local Institution, Suzhou, Jiangsu, 215006, China|Local Institution, Shanghai, Shanghai, 200025, China|Local Institution, Shanghai, Shanghai, 200433, China|Local Institution, Chengdou, Sichuan, 610041, China|Local Institution, Chengdu, Sichuan, 610041, China|Local Institution, Tianjin, Tianjin, 300020, China|Local Institution - 0009, Hangzhou, Zhejiang, 310003, China|Local Institution, Hangzhou, Zhejiang, 310003, China Less <<
NCT01514864 Carcinoma, Non-small Cell Lung PHASE2 TERMINATED 2014-07-23 H. Lee Moffitt Cancer & Resear... More >>ch Institute, Tampa, Florida, 33612, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Memorial Sloan Kettering Nassau, New York, New York, 10065, United States|Local Institution, Barretos, Sao Paulo, 14784-400, Brazil|Local Institution, Barretos, Sao Paulo, 14784, Brazil|Local Institution, S?o Paulo, Sao Paulo, 05403, Brazil|Local Institution, Sao Paulo, 01246-000, Brazil|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, K1H 8L6, Canada|Local Institution, Frankfurt, 60488, Germany|Local Institution, Heidelberg, 69120, Germany|Local Institution, Heidelberg, 69126, Germany|Local Institution, Koeln, 50924, Germany|Local Institution, Koeln, 50931, Germany|Local Institution, Gdansk, 80-219, Poland|Local Institution, Lodz, 93-509, Poland|Local Institution, Warsaw, 02-781, Poland|Local Institution, Taipei, 112, Taiwan|Local Institution, Cambridge, Cambridgeshire, CB2 2QQ, United Kingdom|Local Institution, London, Greater London, SW3 6JJ, United Kingdom|Local Institution, Manchester, Greater Manchester, M20 4BX, United Kingdom|Local Institution, Edinburgh, Midlothian, EH4 2XU, United Kingdom|Local Institution, Sutton, Surrey, SM2 5PT, United Kingdom|Local Institution, Cambridge, CB2 2QQ, United Kingdom|Local Institution, Gwent, NP20 2UB, United Kingdom Less <<
NCT03560908 Relapsed AML|T(8;21)|C-KIT Mut... More >>ation Less << PHASE1 WITHDRAWN 2021-12-31 HBDH, Tianjin, Tianjin, 300020... More >>, China Less <<
NCT01724879 Philadelphia Positive Acute Ly... More >>mphoblastic Leukemia Less << PHASE2 COMPLETED 2025-09-15 Robert Bosch Krankenhaus, Stut... More >>tgart, Baden-Württemberg, 70376, Germany|Klinikum der Universit?t Regensburg, Regensburg, Bayern, 93042, Germany|University Hospital of Frankfurt, Medical Dept. II, Frankfurt, Hessen, 60590, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, 30625, Germany|Universit?tsklinikum Essen, Essen, NRW, 45147, Germany|Universit?tsklinik Münster, Münster, NRW, 48149, Germany|Universit?tsklinik Dresden, Dresden, Sachsen, 01307, Germany|Uniklinik Aachen, Aachen, 52074, Germany|Charité Universit?tsmedizin Berlin, Berlin, 13353, Germany|University Hospital Düsseldorf, Düsseldorf, 40225, Germany|Universit?tsklinikum G?ttingen, G?ttingen, 37075, Germany|Asklepios Klinik St. Georg, Hamburg, 20099, Germany|Universit?tsklinik K?ln, K?ln, 50937, Germany|Universit?t Leipzig, José-Carreras-Haus, Leipzig, 04103, Germany|Universit?tskliniken Mainz, Mainz, 55101, Germany|Klinikum Mannheim, Mannheim, 68167, Germany|Universit?tsklinikum Gro?hadern, München, 81377, Germany|Klinikum Nürnberg Nord, Nürnberg, 90419, Germany|Klinikum Oldenburg, Oldenburg, 26133, Germany|Universit?t Rostock, Rostock, 18055, Germany|Medizinische Universit?tsklinik Ulm, Ulm, 89070, Germany|Medizinische Poliklinik der Universit?t Würzburg, Würzburg, 97070, Germany Less <<
NCT01660906 Chronic Phase Chronic Myeloid ... More >>Leukemia Less << PHASE4 COMPLETED 2025-10-15 Pacific Cancer Medical Center,... More >> Anaheim, California, 92801, United States|Cancer Center Of Central Connecticut, Southington, Connecticut, 06489, United States|St. Agnes Healthcare, Inc., Baltimore, Maryland, 21229, United States|Promedica Hematology & Oncology Assoicates, Sylvania, Ohio, 43560, United States|The University Of Texas Md Anderson Cancer Center, Houston, Texas, 77030, United States|Local Institution, Creteil Cedex, 94010, France|Local Institution, Lille CEDEX, 59037, France|Local Institution, Pierre Benite cedex, 69495, France|Local Institution, Pringy Cedex, 74374, France|Local Institution, Vandoeuvre les Nancy, 54511, France|Local Institution, Jena, 07747, Germany|Local Institution, Koln, 50937, Germany|Local Institution, Lubeck, 23562, Germany|Local Institution, Mannheim, 68169, Germany|Local Institution, Rostock, 18055, Germany|Local Institution, Catania, 95124, Italy|Local Institution, Firenze, 50134, Italy|Local Institution, Napoli, 80131, Italy|Local Institution, Roma, 00144, Italy|Local Institution, Roma, 00161, Italy|Local Institution, Torino, 10126, Italy|Local Institution, Seoul, 137-701, Korea, Republic of Less <<
NCT01609816 Non-Hodgkin's Lymphoma|Multipl... More >>e|Mycosis Fungoides|Hodgkin's Lymphoma|Multiple Myeloma Less << PHASE1 TERMINATED 2018-10-09 Barbara Ann Karmanos Cancer In... More >>stitute, Detroit, Michigan, 48201, United States Less <<
NCT00817531 Breast Cancer PHASE2 TERMINATED 2025-02-11 Baylor College of Medicine, Le... More >>ster and Sue Smith Breast Center, Houston, Texas, 77030, United States Less <<
NCT05993949 Lymphoblastic Leukemia PHASE1 RECRUITING 2025-08-25 Stanford University, Palo Alto... More >>, California, 94305, United States Less <<
NCT04155411 Dasatinib|BCR-ABL|Chronic Myel... More >>oid Leukemia Less << PHASE4 UNKNOWN 2023-12-01 Xin Du, Shenzhen, Guangdong, 5... More >>18000, China Less <<
NCT06055621 Acute Myeloid Leukemia PHASE2 RECRUITING 2025-10-31 Institut Paoli Calmettes, Mars... More >>eille, France Less <<
NCT00858403 Lung Cancer PHASE2 TERMINATED 2025-07-10 H. Lee Moffitt Cancer Center &... More >> Research Institute, Tampa, Florida, 33612, United States Less <<
NCT00978731 Leukemia PHASE1 COMPLETED 2025-09-08 -
NCT00546104 Advanced Breast Cancer PHASE2 COMPLETED 2025-05-11 Palm Beach Cancer Center Insti... More >>tute, West Palm Beach, Florida, 33401, United States|Presbyterian Health Care, Charlotte, North Carolina, 28204, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States Less <<
NCT00777036 Leukemia PHASE2 ACTIVE_NOT_RECRUITING 2029-12-07 Local Institution, Birmingham,... More >> Alabama, 35233, United States|Local Institution - 0005, Phoenix, Arizona, 85016, United States|Phoenix Children'S Hospital, Phoenix, Arizona, 85016, United States|Jonathan Jaques Children'S Cancer Center, Long Beach, California, 90801-1428, United States|Jonathan Jaques Children'S Cancer Center, Long Beach, California, 90806, United States|Local Institution - 0001, Long Beach, California, 90806, United States|Children'S Hospital Of Orange County, Orange, California, 92868, United States|Local Institution - 0024, Orange, California, 92868, United States|Children'S Hospital, Aurora, Colorado, 80045, United States|Local Institution - 0004, Aurora, Colorado, 80045, United States|Children's Healthcare of Atlanta - Egleston Hospital, Atlanta, Georgia, 30322, United States|Children's Healthcare Of Atlanta - Egleston, Atlanta, Georgia, 30322, United States|Children's Hospital of Chicago, Chicago, Illinois, 60611, United States|Local Institution - 0072, Chicago, Illinois, 60611, United States|Local Institution, Chicago, Illinois, 60611, United States|Dana Faber Cancer Institute, Boston, Massachusetts, 02215, United States|Dana Farber Cancer Institute., Boston, Massachusetts, 02215, United States|Local Institution - 0040, Boston, Massachusetts, 02215, United States|Stephen D. Hassenfeld Children'S Center, New York, New York, 10016, United States|Local Institution - 0061, New York, New York, 10021, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Memorial Sloan Kettering Nassau, New York, New York, 10065, United States|Oregon Health & Sci Univ, Portland, Oregon, 97239-3098, United States|Local Institution - 0002, Portland, Oregon, 97239, United States|Oregon Health & Sci Univ, Portland, Oregon, 97239, United States|Children'S Hospital Of Philadelphia, Philadelphia, Pennsylvania, 19104-4318, United States|Local Institution - 0014, Philadelphia, Pennsylvania, 19104-4318, United States|Children'S Hospital Of Pittsburgh, Pittsburgh, Pennsylvania, 15224, United States|Local Institution - 0003, Pittsburgh, Pennsylvania, 15224, United States|Local Institution - 0035, Houston, Texas, 77030-4009, United States|MD Anderson Cancer Center, Houston, Texas, 77030-4009, United States|Local Institution - 0048, Houston, Texas, 77030, United States|Texas Children'S Cancer Center, Houston, Texas, 77030, United States|Local Institution - 0028, Seattle, Washington, 98105, United States|Seattle Children'S, Seattle, Washington, 98105, United States|Local Institution - 0043, Bunos Aires, Buenos Aires, 1425, Argentina|Local Institution, Bunos Aires, Buenos Aires, 1425, Argentina|Hospital Nacional Profesor Alejandro Posadas, El Palomar, Buenos Aires, 1684, Argentina|Local Institution - 0049, El Palomar, Buenos Aires, 1684, Argentina|Local Institution - 0042, Cordoba, 5016, Argentina|Local Institution, Cordoba, 5016, Argentina|Local Institution - 065, Randwick, New South Wales, 2031, Australia|Local Institution, Randwick, New South Wales, 2031, Australia|Local Institution - 069, Westmead, New South Wales, 2145, Australia|Local Institution, Westmead, New South Wales, 2145, Australia|Local Institution - 0064, Sth Brisbane, Queensland, 4101, Australia|Local Institution, Sth Brisbane, Queensland, 4101, Australia|Local Institution - 067, North Adelaide, South Australia, 5006, Australia|Local Institution, North Adelaide, South Australia, 5006, Australia|Local Institution - 0066, Parkville, Victoria, 3052, Australia|Local Institution, Parkville, Victoria, 3052, Australia|Local Institution - 0021, Curitiba, Parana, 80060-900, Brazil|Local Institution, Curitiba, Parana, 80060-900, Brazil|Local Institution - 0022, Porto Alegre, Rio Grande Do Sul, 90035-003, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, 90035-003, Brazil|Local Institution - 0019, S?o Paulo, SAO Paulo, 04520-013, Brazil|Local Institution - 0020, Campinas, 13083-970, Brazil|Local Institution, Campinas, 13083-970, Brazil|Local Institution - 0039, Sao Paulo, 01401-000, Brazil|Local Institution, Sao Paulo, 01401-000, Brazil|Local Institution, Sao Paulo, 04023-062, Brazil|Alberta Children'S Hospital, Calgary, Alberta, T3B 6A8, Canada|Local Institution - 0079, Calgary, Alberta, T3B 6A8, Canada|Local Institution - 0078, Edmonton, Alberta, T6G 2B7, Canada|Stollery Children'S Hospital, Edmonton, Alberta, T6G 2B7, Canada|Bc Children'S Hospital, Vancouver, British Columbia, V6H 3V4, Canada|Local Institution - 077, Vancouver, British Columbia, V6H 3V4, Canada|Iwk Health Centre, Halifax, Nova Scotia, B3K 6R8, Canada|Local Institution - 073, Halifax, Nova Scotia, B3K 6R8, Canada|Children'S Hospital Of Eastern Ontario, Ottawa, Ontario, K1H 8L1, Canada|Local Institution - 086, Ottawa, Ontario, K1H 8L1, Canada|Local Institution - 076, Toronto, Ontario, M5G 1X8, Canada|The Hospital For Sick Children, Toronto, Ontario, M5G 1X8, Canada|Chu Ste-Justine, Montreal, Quebec, H3T 1C5, Canada|Local Institution - 080, Montreal, Quebec, H3T 1C5, Canada|Local Institution - 0030, Lyon, 69008, France|Local Institution, Lyon, 69008, France|Local Institution - 0032, Nantes, 44093, France|Local Institution, Nantes, 44093, France|Local Institution, Paris Cedex 12, 75571, France|Local Institution - 0037, Paris, 75012, France|Local Institution, Paris, 75012, France|Local Institution - 0029, Paris, 75935, France|Local Institution, Paris, 75935, France|Local Institution - 036, Poitiers, 86000, France|Local Institution, Poitiers, 86000, France|Local Institution - 075, Frankfurt, 60590, Germany|Local Institution, Frankfurt, 60590, Germany|Local Institution - 0074, Hannover, 30625, Germany|Local Institution, Hannover, 30625, Germany|Local Institution - 0089, Navrangpura, Ahmedabad, Gujarat, 380009, India|Local Institution, Navrangpura, Ahmedabad, Gujarat, 380009, India|Local Institution, Bangalore, Karnataka, 560027, India|Local Institution, Mumbai, Maharashtra, 400010, India|Local Institution - 0094, Pune, Maharashtra, 411001, India|Local Institution, Pune, Maharashtra, 411001, India|Local Institution - 0093, Madurai, Tamil Nadu, 625107, India|Local Institution, Madurai, Tamil Nadu, 625107, India|Local Institution, Vellore, Tamilnadu, 632004, India|Local Institution - 0088, Bangalore, 560027, India|Local Institution - 0082, Kolkatta, 700 016, India|Local Institution, Kolkatta, 700 016, India|Local Institution - 0085, Mumbai, 400010, India|Local Institution, Mumbai, 400010, India|Local Institution - 0084, Trivandrum, 695011, India|Local Institution, Trivandrum, 695011, India|Local Institution - 038, Bologna, 40138, Italy|Local Institution, Bologna, 40138, Italy|Local Institution, Monza (MB), 20900, Italy|Local Institution - 006, Monza, 20900, Italy|Local Institution - 070, Roma, 00161, Italy|Local Institution, Roma, 00161, Italy|Local Institution - 0059, Roma, 00165, Italy|Local Institution, Roma, 00165, Italy|Local Institution - 015, Torino, 10126, Italy|Local Institution, Torino, 10126, Italy|Local Institution - 0092, Seoul, 05505, Korea, Republic of|Local Institution, Seoul, 05505, Korea, Republic of|Local Institution - 0091, Seoul, 137-701, Korea, Republic of|Local Institution, Seoul, 137-701, Korea, Republic of|Local Institution - 0051, Cuauhtémoc, Distrito Federal, 06720, Mexico|Local Institution, Df, Distrito Federal, 06720, Mexico|Local Institution - 0052, Mexico D.f., Distrito Federal, 06726, Mexico|Local Institution, Mexico D.f., Distrito Federal, 06726, Mexico|Local Institution, Mexico, D. F., Distrito Federal, 06726, Mexico|Local Institution - 0053, Mexico, Distrito Federal, 04530, Mexico|Local Institution, Mexico, Distrito Federal, 04530, Mexico|Hospital Civil De Guadalajara - Nuevo Dr. Juan I. Menchaca, Guadalajara, Jalisco, 44340, Mexico|Local Institution - 0054, Guadalajara, Jalisco, 44340, Mexico|Local Institution - 0060, Monterrey, N.l., Nuevo Leon, 64180, Mexico|Local Institution, Monterrey, N.l., Nuevo Leon, 64180, Mexico|Local Institution - 0050, Monterrey, Nuevo Leon, 64460, Mexico|Local Institution, Monterrey, Nuevo Leon, 64460, Mexico|Local Institution - 0007, Rotterdam, 3015 GJ, Netherlands|Local Institution, Rotterdam, 3015 GJ, Netherlands|Local Institution - 0099, Utrecht, 3584 CS, Netherlands|Local Institution - 0095, Bucharest, 022322, Romania|Local Institution, Bucharest, 022322, Romania|Local Institution - 0097, Sector 2, 022328, Romania|Local Institution - 0017, Moscow, 115478, Russian Federation|Local Institution, Moscow, 115478, Russian Federation|Local Institution - 0023, Moscow, 117198, Russian Federation|Local Institution, Moscow, 117198, Russian Federation|Local Institution - 0018, Saint-petersburg, 197022, Russian Federation|Local Institution, Saint-petersburg, 197022, Russian Federation|Local Institution - 0071, Singapore, 119074, Singapore|Local Institution, Singapore, 119228, Singapore|Local Institution - 0055, Bloemfontein, FREE State, 9301, South Africa|Local Institution, Bloemfontein, FREE State, 9301, South Africa|Local Institution - 058, Pretoria, Gauteng, 0001, South Africa|Local Institution, Pretoria, Gauteng, 0001, South Africa|Local Institution - 0057, Cape Town, Western CAPE, 7925, South Africa|Local Institution, Cape Town, Western CAPE, 7925, South Africa|Local Institution - 062, Tygerberg, Western CAPE, 7505, South Africa|Local Institution, Tygerberg, Western CAPE, 7505, South Africa|Local Institution - 0013, Barcelona, 08025, Spain|Local Institution, Barcelona, 08025, Spain|Local Institution - 0012, Barcelona, 08035, Spain|Local Institution, Barcelona, 08035, Spain|Local Institution - 0011, Madrid, 28009, Spain|Local Institution, Madrid, 28009, Spain|Local Institution - 0010, Madrid, 28046, Spain|Local Institution, Madrid, 28046, Spain|Local Institution - 0041, Malaga, 29010, Spain|Local Institution, Malaga, 29010, Spain|Local Institution - 0033, Valencia, 46009, Spain|Local Institution, Valencia, 46009, Spain|Local Institution, Valencia, Spain|Local Institution - 0016, Glasgow, Central, G3 8SJ, United Kingdom|Local Institution, Glasgow, Central, G3 8SJ, United Kingdom|Local Institution - 0009, Sutton, Surrey, SM2 5PT, United Kingdom|Local Institution, Sutton, Surrey, SM2 5PT, United Kingdom|Local Institution - 0008, Birmingham, West Midlands, B4 6NH, United Kingdom|Local Institution, Birmingham, West Midlands, B4 6NH, United Kingdom Less <<
NCT00438854 Chronic Lymphocytic Leukemia PHASE2 COMPLETED 2025-03-13 Massachusetts General Hospital... More >>, Boston, Massachusetts, 02114, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States Less <<
NCT00101660 Chronic Myeloid Leukemia|Phila... More >>delphia-Positive Myeloid Leukemia Less << PHASE2 COMPLETED 2025-04-08 Local Institution, Anaheim, Ca... More >>lifornia, United States|Local Institution, Loma Linda, California, United States|Local Institution, Los Angeles, California, United States|Local Institution, Stanford, California, United States|Local Institution, Vallejo, California, United States|Local Institution, Hartford, Connecticut, United States|Local Institution, Washington, District of Columbia, United States|Local Institution, Jacksonville, Florida, United States|Local Institution, Tampa, Florida, United States|Local Institution, Atlanta, Georgia, United States|Local Institution, Chicago, Illinois, United States|Local Institution, Indianapolis, Indiana, United States|Local Institution, Kansas City, Kansas, United States|Local Institution, Baltimore, Maryland, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Detroit, Michigan, United States|Local Institution, Kansas City, Missouri, United States|Local Institution, St. Louis, Missouri, United States|Local Institution, Omaha, Nebraska, United States|Local Institution, Hackensack, New Jersey, United States|Local Institution, New Brunswick, New Jersey, United States|Local Institution, New York, New York, United States|Local Institution, Portland, Oregon, United States|Local Institution, Philadelphia, Pennsylvania, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Local Institution, Greenville, South Carolina, United States|Local Institution, Nashville, Tennessee, United States|Local Institution, Dallas, Texas, United States|Local Institution, Houston, Texas, United States|Local Institution, San Antonio, Texas, United States|Local Institution, Tyler, Texas, United States|Local Institution, Spokane, Washington, United States|Local Institution, St. Leonards, New South Wales, Australia|Local Institution, South Brisbane, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, East Mebourne, Victoria, Australia|Local Institution, Parkville, Victoria, Australia|Local Institution, Wein, Austria|Local Institution, B-Leuven, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Edegem, Belgium|Local Institution, Yvoir, Belgium|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Aarhus, Denmark|Local Institution, Helsinki, Finland|Local Institution, Lille Cedex, France|Local Institution, Lyon Cedex 03, France|Local Institution, Nantes, France|Local Institution, Paris Cedex 10, France|Local Institution, Pessac, France|Local Institution, Poitiers Cedex, France|Local Institution, Strasbourg Cedex, France|Local Institution, Hamburg, Germany|Local Institution, Leipzig, Germany|Local Institution, Mainz, Germany|Local Institution, Mannheim, Germany|Local Institution, Co Galway, Galway, Ireland|Local Institution, Dublin, Ireland|Local Institution, Ramat-Gan, Israel|Local Institution, Bari, Italy|Local Institution, Bologna, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Orbassano, Italy|Local Institution, Roma, Italy|Local Institution, Kyunggi-Do, Korea, Republic of|Local Institution, Nijmegen, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Trondheim, Norway|Local Institution, Lima, Peru|Local Institution, Singapore, Singapore|Local Institution, Parktown, Gauteng, South Africa|Local Institution, Soweto, Gauteng, South Africa|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Gothenburg, Sweden|Local Institution, Lund, Sweden|Local Institution, Stockholm, Sweden|Local Institution, Umea, Sweden|Local Institution, Uppsala, Sweden|Local Instituion, Basel, Switzerland|Local Institution, Glasgow, Central, United Kingdom|Local Institution, London, Greater London, United Kingdom Less <<
NCT02268370 Chronic Myeloid Leukemia PHASE2 UNKNOWN 2025-10-21 Tom Baker Cancer Center, Calga... More >>ry, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, V5Z1M9, Canada|Cancer Care Manitoba, Winnipeg, Manitoba, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Ottawa General Hospital, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2M9, Canada|Centre H?pitallier Universitaire de Quebec - H?pital de l'Enfant-Jésus, Charlesbourg, Quebec, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|McGill University Health Centre, Montreal, Quebec, Canada Less <<
NCT01826838 Prostate Cancer PHASE1 WITHDRAWN 2025-04-13 -
NCT01802450 Chronic Myeloid Leukemia PHASE2 UNKNOWN 2025-12-16 Hospital Txagorritxu, Vitoria,... More >> Alava, 01010, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, 33006, Spain|Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|Complejo Hospitalario de Toledo - Hospital Virgen de la Salud, Toledo, Castilla La Mancha, 45004, Spain|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, La Coru?a, 15706, Spain|Hospital San Pedro de La Rioja, Logro?o, La Rioja, 26006, Spain|Hospital POVISA, Vigo, Pontevedra, 36211, Spain|Institut Catalá d'Oncologia L'Hospitallet, Barcelona, 08907, Spain|Hospital de León, León, 24071, Spain|Hospital Universitario de la Princesa, Madrid, 28006, Spain|Hospital Universitario Ramón y Cajal, Madrid, 28034, Spain|Hospital 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario La Paz, Madrid, 28046, Spain|Hospital Universitario de Salamanca, Salamanca, 37007, Spain|Hospital Virgen del Rocío, Sevilla, 41013, Spain Less <<
NCT01491633 Squamous Cell Lung Cancer PHASE2 TERMINATED 2025-05-13 Massachusetts General Hospital... More >>, Boston, Massachusetts, 02114, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States Less <<
NCT00429949 Relapsed, Refractory or Platea... More >>u Phase Multiple Myeloma Less << PHASE2 COMPLETED 2025-01-08 Washington Universtiy in St. L... More >>ouis, St. Louis, Missouri, 63110, United States Less <<
NCT04115059 Waldenstrom Macroglobulinemia|... More >>DASATINIB Less << PHASE1 TERMINATED 2021-12-31 Dana Farber Cancer Institute, ... More >>Boston, Massachusetts, 02215, United States Less <<
NCT03625388 Chronic Myelogenous Leukemia PHASE2 COMPLETED 2023-07-22 King Hussein Cancer Center (KH... More >>CC), Amman, 11941, Jordan|Jordan University Hospital (JUH), Amman, 11942, Jordan|American University of Beirut Medical Center (AUBMC), Beirut, Lebanon|The King Faisal Specialist Hospital and Research Centre (KFSH&RC), Riyadh, Saudi Arabia|Aziza Othmana Hospital, Tunis, 1006, Tunisia Less <<
NCT01410708 Breast Cancer PHASE2 WITHDRAWN - Cross Cancer Institute, Edmont... More >>on, Alberta, Canada Less <<
NCT01916785 Chronic Myelogenous Leukemia, ... More >>BCR/ABL Positive Less << PHASE2 COMPLETED 2025-12-13 Southern Alberta Cancer Resear... More >>ch Institute, Calgary, Canada|H?pital Charles LeMoyne, Greenfield Park, Canada|Queen elisabeth II Health Sciences Center, Halifax, Canada|CH Pierre LeGardeur, Lachenaie, Canada|Moncton City Hospital, Moncton, Canada|H?pital Général Juif - Sir. Mortimer B. Davis, Montréal, Canada|H?pital Maisonneuve-Rosemont, Montréal, Canada|H?pital Royal Victoria, Montréal, Canada|H?pital de l'Enfant Jésus - Centre hospitalier affilié universitaire de Québec, Québec, Canada|Pavillon H?tel-Dieu de Québec - Centre hospitalier universitaire de Québec, Québec, Canada|CHU Angers, Angers, France|H?pital Avicenne, Bobigny, France|Institut Bergonie, Bordeaux, France|Hopital MORVAN, Brest, France|CH René Dubos, Cergy Pontoise, France|H?pital d'Instruction de Armées Percy, Clamart, France|Hopital Henri MONDOR, Creteil, France|H?pital Claude Huriez, Lille, France|CH Lyon Sud, Lyon, France|Institut Paoli-Calmettes, Marseille, France|H?pital d'Annecy, Metz Tessy, France|C.H.U. Brabois, Nancy, France|CHU Hoptel dieu, Nantes, France|H?pital l'Archet 1, Nice, France|CHU Caremeau, Nimes, France|Hopital Saint Louis, Paris, France|H?pital Necker-Enfants Malades, Paris, France|H?pital St Antoine, Paris, France|CHU Poitiers, Poitiers, France|CHU Rennes - Pontchaillou, Rennes, France|Centre René Huguenin, Saint Cloud, France|H?pital Purpan, Toulouse, France|CHRU Bretonneau, Tours, France|Central Hospital, Versailles, France Less <<
NCT00564876 Carcinoma, Non-Small-Cell Lung PHASE2 TERMINATED 2025-09-09 Duke University Medical Center... More >>, Durham, North Carolina, 27710, United States Less <<
NCT00298987 Leukemia, Myeloid, Chronic|Leu... More >>kemia, Lymphocytic, Acute, L2 Less << PHASE2 COMPLETED 2025-06-07 Local Institution, Corona, Cal... More >>ifornia, United States|Local Institution, Aurora, Colorado, United States|Local Institution, Colorado Springs, Colorado, United States|Local Institution, Waterford, Connecticut, United States|Local Institution, Daytona Beach, Florida, United States|Local Institution, Jupiter, Florida, United States|Local Institution, Atlanta, Georgia, United States|Local Institution, Lawrenceville, Georgia, United States|Local Institution, Beach Grove, Indiana, United States|Local Institution, Indianapolis, Indiana, United States|Local Institution, Iowa City, Iowa, United States|Local Institution, Kansas City, Kansas, United States|Local Institution, Salina, Kansas, United States|Local Institution, Lexington, Kentucky, United States|Local Institution, Louisville, Kentucky, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Ann Arbor, Michigan, United States|Local Institution, Detroit, Michigan, United States|Local Institution, Santa Fe, New Mexico, United States|Local Institution, New York, New York, United States|Local Institution, Cincinnati, Ohio, United States|Local Institution, Cleveland, Ohio, United States|Local Institution, Lawton, Oklahoma, United States|Local Institution, Tulsa, Oklahoma, United States|Local Institution, Portland, Oregon, United States|Local Institution, Providence, Rhode Island, United States|Local Institution, Charleston, South Carolina, United States|Local Institution, Chattanooga, Tennessee, United States|Local Institution, Spokane, Washington, United States|Local Institution, Sheboygan, Wisconsin, United States|Local Institution, Edmonton, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Hamilton, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada Less <<
NCT00349518 Chronic Myeloid Leukemia|Acute... More >> Lymphoblastic Leukemia Less << PHASE2|PHASE3 WITHDRAWN - Local Institution, Budapest, H... More >>ungary|Local Institution, Bologna, Italy|Local Institution, Orbassano (To), Italy|Local Institution, Roma, Italy|Local Institution, Nijmegen, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Gdansk, Poland|Local Institution, Katowice, Poland|Local Institution, Krakow, Poland|Local Instiution, Lodz, Poland|Local Institution, Lublin, Poland|Local Institution, Warsaw, Poland|Local Institution, Moscow, Russian Federation|Local Institution, St.Petersburg, Russian Federation|Local Institution, Cambridge, Cambridgeshire, United Kingdom|Local Institution, Glasgow, Central, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Liverpool, Merseyside, United Kingdom|Local Institution, Newcastle, Tyne And Wear, United Kingdom|Local Institution, Birmingham, West Midlands, United Kingdom Less <<
NCT01051115 Chronic Lymphocytic Leukemia PHASE2 UNKNOWN 2025-01-16 Maastricht university medical ... More >>center, Maastricht, Limburg, 6229 HX, Netherlands|Academic Medical Center, Amsterdam, NH, 1105 AZ, Netherlands|Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, ZH, 3015 CE, Netherlands|University Medical Center Groningen, Groningen, 9713 GZ, Netherlands Less <<
NCT02428855 Cholangiocarcinoma PHASE2 COMPLETED 2025-02-18 Massachusetts General Hospital... More >>, Boston, Massachusetts, 02114, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States Less <<
NCT00101816 Chronic Myeloid Leukemia|Blast... More >> Crisis Less << PHASE2 COMPLETED 2025-03-08 Local Institution, Birmingham,... More >> Alabama, United States|Local Institution, Anaheim, California, United States|Local Institution, Los Angeles, California, United States|Local Institution, Stanford, California, United States|Local Institution, Vallejo, California, United States|Local Institution, Denver, Colorado, United States|Local Institution, Jacksonville, Florida, United States|Local Institution, Tampa, Florida, United States|Local Institution, Atlanta, Georgia, United States|Local Institution, Chicago, Illinois, United States|Local Institution, Kansas City, Kansas, United States|Local Institution, Baltimore, Maryland, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Detroit, Michigan, United States|Local Institution, St. Louis, Missouri, United States|Local Institution, Hackensack, New Jersey, United States|Local Institution, New Brunswick, New Jersey, United States|Local Institution, New York, New York, United States|Local Institution, Portland, Oregon, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Local Institution, Nashville, Tennessee, United States|Local Institution, Houston, Texas, United States|Local Institution, Seattle, Washington, United States|Local Institution, Adelaide, South Australia, Australia|Local Institution, Wien, Austria|Local Institution, B-Leuven, Belgium|Local Institution, Edegem, Belgium|Local Institution, Montreal, Quebec, Canada|Local Institution, Aarhus, Denmark|Local Institution, Helsinki, Finland|Local Institution, Lille, France|Local Institution, Lyon Cedex 03, France|Local Institution, Nantes, France|Local Institution, Paris Cedex 10, France|Local Institution, Pessac, France|Local Institution, Poitiers Cedex, France|Local Institution, Strasbourg Cedex, France|Local Institution, Hamburg, Germany|Local Institution, Mainz, Germany|Local Institution, Mannheim, Germany|Local Institution, Ramat-Gan, Israel|Local Institution, Bologna, Italy|Local Institution, Napoli, Italy|Local Institution, Orbassano, Italy|Local Institution, Roma, Italy|Local Institution, Jeollanam-Do, Korea, Republic of|Local Institution, Kyunggi-Do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Nijmegen, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Trondheim, Norway|Local Institution, Quezon City, Philippines|Local Institution, Singapore, Singapore|Local Institution, Gothenburg, Sweden|Local Institution, Lund, Sweden|Local Institution, Umea, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Basel, Switzerland|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Glasgow, Central, United Kingdom|Local Institution, London, Greater London, United Kingdom Less <<
NCT00103701 Leukemia, Myeloid, Chronic-pha... More >>se|Leukemia, Lymphoblastic, Acute, Philadelphia-positive Less << PHASE1 COMPLETED 2025-03-06 Local Institution, Los Angeles... More >>, California, United States|Local Institution, Houston, Texas, United States Less <<
NCT00624585 Myelodysplastic Syndromes COMPLETED 2025-05-12 H. Lee Moffitt Cancer Center a... More >>nd Research Institute, Tampa, Florida, 33612, United States Less <<
NCT01471106 Breast Cancer PHASE2 COMPLETED 2024-05-30 Duke University, Durham, North... More >> Carolina, 27708, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States Less <<
NCT00464620 Rhabdomyosarcoma|Malignant Per... More >>ipheral Nerve Sheath Tumors|Chondrosarcoma|Sarcoma, Ewing's|Sarcoma, Alveolar Soft Part|Chordoma|Epithelioid Sarcoma|Giant Cell Tumor of Bone|Hemangiopericytoma|Gastrointestinal Stromal Tumor (GIST) Less << PHASE2 COMPLETED 2025-05-17 Arkansas Children's Hospital, ... More >>Little Rock, Arkansas, 72202, United States|City of Hope, Duarte, California, 91010, United States|Cedars-Sinai Outpatient Cancer Center, Los Angeles, California, 90048, United States|Stanford University, Palo Alto, California, 94304, United States|Sarcoma Oncology Center, Santa Monica, California, 90403, United States|Washington Cancer Institute, Washington, District of Columbia, 20010, United States|Winship Cancer Institute at Emory University, Atlanta, Georgia, 30308, United States|Kootenai Cancer Center, Coeur d'Alene, Idaho, 83814, United States|Oncology Specialists, Park Ridge, Illinois, 60068, United States|Indiana University Cancer Center, Indianapolis, Indiana, 46202, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, 52242, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, 21231, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Nebraska Methodist Hospital, Omaha, Nebraska, 68114, United States|Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, 19106, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15232, United States|MD Anderson, Houston, Texas, 77030, United States Less <<
NCT00652574 Malignant Pleural Mesothelioma PHASE1 COMPLETED 2022-10-07 University of Texas MD Anderso... More >>n Cancer Center, Houston, Texas, 77030, United States Less <<
NCT00101595 Chronic Myeloid Leukemia|Leuke... More >>mia, Lymphoblastic, Acute, Philadelphia-positive Less << PHASE2 COMPLETED 2025-12-07 Local Institution, Birmingham,... More >> Alabama, United States|Local Institution, Anaheim, California, United States|Local Institution, Los Angeles, California, United States|Local Institution, Stanford, California, United States|Local Institution, Vallejo, California, United States|Local Institution, Jacksonville, Florida, United States|Local Institution, Tampa, Florida, United States|Local Institution, Atlanta, Georgia, United States|Local Institution, Chicago, Illinois, United States|Local Institution, Kansas City, Kansas, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, St. Louis, Missouri, United States|Local Institution, Hackensack, New Jersey, United States|Local Institution, New York, New York, United States|Local Institution, Portland, Oregon, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Local Institution, Nashville, Tennessee, United States|Local Institution, Houston, Texas, United States|Local Institution, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, St. Leonards, New South Wales, Australia|Local Institution, Wien, Austria|Local Institution, B-Leuven, Belgium|Local Institution, Edegem, Belgium|Local Institution, Yvoir, Belgium|Local Institution, Campinas, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Aarhus, Denmark|Local Institution, Helsinki, Finland|Local Institution, Lille, France|Local Institution, Lyon Cedex 03, France|Local Institution, Nantes, France|Local Institution, Paris, France|Local Institution, Pessac, France|Local Institution, Poitiers Cedex, France|Local Institution, Strasbourg Cedex, France|Local Institution, Frankfurt/Main, Germany|Local Institution, Hamburg, Germany|Local Institution, Mainz, Germany|Local Institution, Mannheim, Germany|Local Institution, Ramat-Gan, Israel|Local Institution, Bologna, Italy|Local Institution, Orbassano, Italy|Local Institution, Roma, Italy|Local Institution, Kyunggi-Do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Nijmegen, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Trondheim, Norway|Local Institution, Lima, Peru|Local Institution, Gothenburg, Sweden|Local Institution, Lund, Sweden|Local Institution, Stockholm, Sweden|Local Institution, Umea, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Basel, Switzerland|Local Institution, Glasgow, Central, United Kingdom|Local Institution, London, Greater London, United Kingdom Less <<
NCT01460160 Leukemia, Pediatric PHASE2 COMPLETED 2021-06-01 University Of Alabama At Birmi... More >>ngham, Birmingham, Alabama, 35233, United States|Phoenix Children'S Hospital/Ctr. For Cancer & Blood Ctr., Phoenix, Arizona, 85016, United States|University Of Arkansas For Medical Sciences, Little Rock, Arkansas, 72202, United States|Antranik Agop Bedros, Loma Linda, California, 92350, United States|Miller Children's and Women Hospital, Long Beach, California, 90806, United States|Children'S Hospital Of L.A., Los Angeles, California, 90027, United States|Southern California Permanente Medical Group, Los Angeles, California, 90027, United States|Valley Children's Hospital, Madera, California, 93636, United States|Children's Hospital of Orange County, Orange, California, 92868, United States|Lpch & Sumc, Palo Alto, California, 94304, United States|Kaiser Medical Center, Roseville, California, 95661, United States|Ucsf - Hematology/Oncology, San Francisco, California, 94143-0106, United States|Children'S Hospital Colorado, Aurora, Colorado, 80045, United States|Connecticut Children's Medical Center, Hartford, Connecticut, 06106, United States|A. I. Dupont Hospital For Children, Wilmington, Delaware, 19803, United States|Children'S National Medical Center, Washington, District of Columbia, 20010, United States|Lee Memorial Health System, Fort Myers, Florida, 33908, United States|University Of Florida, Gainesville, Florida, 32610, United States|Nemours Children'S Clinic, Jacksonville, Florida, 32207, United States|Md Anderson Cancer Center Orlando, Orlando, Florida, 32806, United States|Nemours Childrens Hospital, Orlando, Florida, 32827, United States|All Children'S Hospital, Saint Petersburg, Florida, 33629, United States|St. Joseph's Children's Hospital, Tampa, Florida, 33607, United States|St. Mary'S, West Palm Beach, Florida, 33407, United States|Children's Healthcare Of Atlanta, Atlanta, Georgia, 30322, United States|Kapiolani Medical Center For Women & Children, Honolulu, Hawaii, 96826, United States|Mountain States Tumor Institute, Boise, Idaho, 83712, United States|Ann & Robert H Lurie Children's Hospital Of Chicago, Chicago, Illinois, 60611, United States|Loyola University Medical Center, Maywood, Illinois, 60153, United States|Southern Illinois University School Of Medicine, Springfield, Illinois, 62794-9635, United States|James Whitcomb Riley Hospital For Children, Indianapolis, Indiana, 46202-5225, United States|Children'S Center For Cancer And Blood Diseases, Indianapolis, Indiana, 46260, United States|University Of Kentucky, Lexington, Kentucky, 40536-0284, United States|Norton Children's Hospital, Louisville, Kentucky, 40202, United States|Sinai Hospital Of Baltimore, Baltimore, Maryland, 21215, United States|Johns Hopkins University, Baltimore, Maryland, 21231, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|UMass Memorial Medical Center, Worcester, Massachusetts, 01655, United States|Children'S Hospital Of Michigan, Detroit, Michigan, 48201, United States|Helen Devos Children'S Hospital, Grand Rapids, Michigan, 49503, United States|Michigan State University, Lansing, Michigan, 48912, United States|Childrens Hospitals And Clinics Of Minnesota, Minneapolis, Minnesota, 55404, United States|Univ Of Mississippi Med Ctr, Jackson, Mississippi, 39216, United States|University Of Missouri Health Care, Columbia, Missouri, 65212, United States|Children'S Mercy Hospital And Clinics, Kansas City, Missouri, 64108, United States|Washington University Medical Center, Saint Louis, Missouri, 63110, United States|Children'S Specialty Center Of Nevada, Las Vegas, Nevada, 89109, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Goryeb Children'S Hospital, Morristown, New Jersey, 07962, United States|The Cancer Institute Of New Jersey, New Brunswick, New Jersey, 08901, United States|Newark Beth Israel Medical Center, Newark, New Jersey, 07112, United States|St. Joseph's Regional Medical Center, Paterson, New Jersey, 07503, United States|University Of New Mexico, Albuquerque, New Mexico, 87131-0001, United States|New York University, New York, New York, 10016, United States|The Herbert Irving Pavilion, New York, New York, 10032, United States|New York Presbyterian/Weill Cornell, New York, New York, 10065, United States|SUNY Upstate Medical University, Syracuse, New York, 13210, United States|New York Medical College, Valhalla, New York, 10595, United States|Levine Children's Hospital, Charlotte, North Carolina, 28203, United States|Wake Forest University, Winston-Salem, North Carolina, 27157-1081, United States|Cincinnati Children'S Hospital Medical Center, Cincinnati, Ohio, 45229-3039, United States|Nationwide Children'S Hospital, Columbus, Ohio, 43205, United States|The Children'S Medical Center Of Dayton, Dayton, Ohio, 45404-1815, United States|The Toledo Children'S Hospital, Toledo, Ohio, 43606, United States|Mercy Children's Hospital, Toledo, Ohio, 43608, United States|University Of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, 73104, United States|Legacy Emanuel Hospital & Health Center, Portland, Oregon, 97227, United States|Oregon Health & Sci Univ, Portland, Oregon, 97239, United States|Geisinger Medical Center, Danville, Pennsylvania, 17822-1320, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, 17033, United States|Children'S Hospital Of Philadelphia, Philadelphia, Pennsylvania, 19104-4318, United States|Children's Hospital Of Pittsburgh Of UPMC, Pittsburgh, Pennsylvania, 15224, United States|Rhode Island Hospital, Providence, Rhode Island, 02903, United States|East Tennessee Children'S Hosp, Knoxville, Tennessee, 37916, United States|Vanderbilt University, Nashville, Tennessee, 37232-6310, United States|Dell Children'S Medical Center Of Central Texas, Austin, Texas, 78723, United States|Driscoll Children'S Hospital, Corpus Christi, Texas, 78411, United States|Ut Southwestern, Dallas, Texas, 75390-9063, United States|Cook Children'S Hem/Onc Center, Fort Worth, Texas, 76104, United States|Texas Children'S Cancer Center, Houston, Texas, 77030, United States|Scott & White - McLane Children's Specialty Clinic, Temple, Texas, 76508, United States|Primary Children's Medical Center, Salt Lake City, Utah, 84113, United States|Inova Pediatric Specialty Center Ii, Fairfax, Virginia, 22031, United States|Children'S Hosp-Kings Daughter, Norfolk, Virginia, 23507, United States|Seattle Children'S, Seattle, Washington, 98105, United States|St Vincent Hospital, Green Bay, Wisconsin, 54301, United States|Kenneth Desantes, Md, Madison, Wisconsin, 53705-2275, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States|Local Institution, Sth Brisbane, Queensland, 4101, Australia|Local Institution, Parkville, Victoria, 3052, Australia|Local Institution, Nedlands, Western Australia, 6009, Australia|Alberta Children'S Hospital, Calgary, Alberta, T3B 6A8, Canada|Stollery Children'S Hospital, Edmonton, Alberta, T6G 2B7, Canada|Local Institution, London, Ontario, N6A 5W9, Canada|Children'S Hospital Of Eastern Ontario, Ottawa, Ontario, K1H 8L1, Canada|Chu Ste-Justine, Montreal, Quebec, H3T 1C5, Canada|The Montreal Children's Hospital of the MUHC, Montreal, Quebec, H4A 3J1, Canada|Local Institution, Saskatoon, Saskatchewan, S7N 4H4, Canada|Local Institution, Bologna, 40138, Italy|Local Institution, Cagliari, 09121, Italy|Local Institution, Catania, 95123, Italy|Local Institution, Firenze, 50139, Italy|Local Institution, Genova, 16147, Italy|Local Institution, Monza, 20900, Italy|Local Institution, Napoli, 80123, Italy|Local Institution, Palermo, 90134, Italy|Local Institution, Roma, 00161, Italy|Local Institution, Roma, 00165, Italy|Local Institution, Torino, 10126, Italy|Local Institution, Trieste, 34137, Italy|Local Institution, San Juan, 00912, Puerto Rico|Local Institution, Bristol, Avon, BS2 8BJ, United Kingdom|Local Institution, Cardiff, Glamorgan, CF14 4XW, United Kingdom|Local Institution, Aberdeen, Grampian, AB25 2ZG, United Kingdom|Local Institution, London, Greater London, WC1N3JH, United Kingdom|Local Institution, Manchester, Greater Manchester, M27 4HA, United Kingdom|Local Institution, Southampton, Hampshire, SO9 4XY, United Kingdom|Local Institution, Glasgow, Lanarkshire, G3 8SJ, United Kingdom|Local Institution, Edinburgh, Lothian, EH9 1LF, United Kingdom|Local Institution, Liverpool, Merseyside, L12 2AP, United Kingdom|Local Institution, Leeds, North Yorkshire, LS1 3EX, United Kingdom|Local Institution, Nottingham, Nottinghamshire, NG7 2UH, United Kingdom|Local Institution, Oxford, Oxfordshire, OX 39DU, United Kingdom|Local Institution, Sheffield, South Yorkshire, S10 2TH, United Kingdom|Local Institution, Sutton, Surrey, SM2 5PT, United Kingdom|Local Institution, Newcastle-upon-tyne, Tyne And Wear, NE1 4LP, United Kingdom|Local Institution, Birmingham, West Midlands, B4 6NH, United Kingdom|Local Institution, Cambridge, CB2 2QQ, United Kingdom Less <<
NCT00101647 Chronic Myelogenous Leukemia PHASE2 COMPLETED 2025-03-08 Local Institution, Birmingham,... More >> Alabama, United States|Local Institution, Anaheim, California, United States|Local Institution, Los Angeles, California, United States|Local Institution, Stanford, California, United States|Local Institution, Vallejo, California, United States|Local Institution, Jacksonville, Florida, United States|Local Institution, Tampa, Florida, United States|Local Institution, Atlanta, Georgia, United States|Local Institution, Chicago, Illinois, United States|Local Institution, Kansas City, Kansas, United States|Local Institution, Baltimore, Maryland, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Detroit, Michigan, United States|Local Institution, St. Louis, Missouri, United States|Local Institution, Hackensack, New Jersey, United States|Local Institution, New York, New York, United States|Local Institution, Portland, Oregon, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Local Institution, Nashville, Tennessee, United States|Local Institution, Dallas, Texas, United States|Local Institution, Houston, Texas, United States|Local Institution, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, St. Leonards, New South Wales, Australia|Local Institution, South Brisbane, Queensland, Australia|Local Institution, East Melbourne, Victoria, Australia|Local Institution, Parkville, Victoria, Australia|Local Institution, Wien, Australia|Local Institution, B-Leuven, Belgium|Local Institution, Edegem, Belgium|Local Institution, Campinas, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Toronto, Ontario, Canada|Local Institution, Aarhus, Denmark|Local Institution, Helsinki, Finland|Local Institution, LIlle, France|Local Institution, Lyon Cedex 03, France|Local Institution, Nantes, France|Local Institution, Paris, France|Local Institution, Pessac, France|Local Institution, Poitiers Cedex, France|Local Institution, Strasbourg Cedex, France|Local Institution, Hamburg, Germany|Local Institution, Mainz, Germany|Local Institution, Mannheim, Germany|Local Institution, Ramat-Gan, Israel|Local Institution, Bologna, Italy|Local Institution, Napoli, Italy|Local Institution, Orbassano, Italy|Local Institution, Roma, Italy|Local Institution, Jeollanam-Do, Korea, Republic of|Local Institution, Kyunggi-Do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Nijmegen, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Trondheim, Norway|Local Institution, Lima, Peru|Local Institution, Quezon City, Philippines|Local Institution, Singapore, Singapore|Local Institution, Gothenburg, Sweden|Local Institution, Lund, Sweden|Local Institution, Umea, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Basel, Switzerland|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Bangkok, Thailand|Local Institution, Glasgow, Central, United Kingdom|Local Institution, London, Greater London, United Kingdom Less <<
NCT02546791 Leukemia COMPLETED 2017-03-29 -
NCT00570700 Hormone-refractory Prostate Ca... More >>ncer|Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Prostate Cancer|Recurrent Prostate Cancer Less << PHASE2 COMPLETED 2025-02-12 City of Hope National Medical ... More >>Center, Duarte, California, 91010, United States|Loma Linda University Cancer Center, Loma Linda, California, 92354, United States|Chao Family Comprehensive Cancer Center, Orange, California, 92868, United States|St. Joseph Hospital, Orange, California, 92868, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, 15232, United States|Medical University of South Carolina, and Hollings Cancer Network, Charleston, South Carolina, 29425, United States Less <<
NCT01850004 Chronic Phase Chronic Myeloid ... More >>Leukemia Less << PHASE2 COMPLETED 2021-10-08 Local Institution - 0006, Duar... More >>te, California, 91010, United States|Local Institution - 0029, Los Angeles, California, 90095, United States|Local Institution - 0001, San Franisco, California, 94143, United States|Local Institution - 0013, Chicago, Illinois, 60611, United States|Local Institution - 0024, Hackensack, New Jersey, 07601, United States|Local Institution - 0028, New York, New York, 10032, United States|Local Institution - 0011, Dallas, Texas, 75246, United States|Local Institution - 0023, Houston, Texas, 77030-4000, United States|Local Institution - 0005, Toronto, Ontario, M5G 2M9, Canada|Local Institution - 0012, Paris, 75475, France|Local Institution - 0003, Pessac, 33604, France|Local Institution - 0030, Pierre Benite Cedex, 69495, France|Local Institution - 0002, Vandoeuvre-les-Nancy CEDEX, 54511, France|Local Institution - 0019, Rostock, Mecklenburg Vorpommern, 18057, Germany|Local Institution - 0026, Aachen, D-52074, Germany|Local Institution - 0020, Berlin, 13353, Germany|Local Institution - 0021, Mannheim, 68167, Germany|Local Institution - 0022, Ulm, 89081, Germany|Local Institution - 0025, Catania, 95123, Italy|Local Institution - 0017, Firenze, 50134, Italy|Local Institution - 0027, Napoli, 80131, Italy|Local Institution - 0015, Orbassano, 10143, Italy|Local Institution - 0018, Roma, 00144, Italy|Local Institution - 0016, Rome, 00161, Italy|Local Institution - 0014, Oviedo, Asturias, 33011, Spain|Local Institution - 0009, Las Palmas de Gran Canaria, 35010, Spain|Local Institution - 0010, Madrid, 28034, Spain|Local Institution - 0008, Malaga, 29010, Spain Less <<
NCT04439305 Advanced Lymphoma|Advanced Mal... More >>ignant Solid Neoplasm|Hematopoietic and Lymphoid Cell Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Plasma Cell Myeloma Less << PHASE2 WITHDRAWN - ECOG-ACRIN Cancer Research Gro... More >>up, Philadelphia, Pennsylvania, 19103, United States Less <<
NCT02297139 Multiple Indications Cancer PHASE2 COMPLETED 2022-05-15 Local Institution, Besancon, 2... More >>5000, France|Local Institution - 0006, Kraków, Ma?opolskie, 30-727, Poland|Local Institution, Chorzow, 41-500, Poland|Local Institution, Lodz, 93-510, Poland|Local Institution - 0003, Warsaw, 02776, Poland|Local Institution - 0002, Wroclaw, 50-367, Poland Less <<
NCT02888990 Leukemia, Lymphoblastic, Acute PHASE2 COMPLETED 2025-01-16 Cliniques Universitaires Saint... More >>-Luc, Bruxelles, Belgium|CHU Ambroise Paré, Mons, Belgium|Centre Hospitalier Départemental FELIX GUYON, St Denis, La Reunion, France|Ch D'Aix En Provence, Aix en provence, France|Groupe Hospitalier Sud, Amiens, France|CHU Angers, Angers, France|Chr Annecienne, Annecy, France|Ch Victor Dupouy, Argenteuil, France|CHG D'Avignon Henri Duffaut, Avignon, France|C.H. de la C?te Basque, Bayonne, France|H?pital JEAN MINJOZ, Besancon, France|CH Blois, Blois, France|Avicenne, Bobigny, France|CHU Brest, Brest, France|H?pital CLEMENCEAU, Caen, France|HIA Percy, Clamart, France|Hotel Dieu, Clermont ferrand, France|H?pital PASTEUR, Colmar, France|Centre Hospitalier Sud Francilien, Corbeil Essonnes, France|Henry Mondor, Creteil, France|H?pital du BOCAGE, Dijon, France|CH Dunkerque, Dunkerque, France|H?pital A. MICHALLON, Grenoble, France|CH Versailles, Le Chesnay, France|CH Lens, Lens, France|Hopital Claude Huriez, Lille, France|H?pital Dupuytren, Limoges, France|Edouard Herriot, Lyon, France|IPC, Marseille, France|CH Meaux, Meaux, France|H?pital Notre Dame de Bon Secours, Metz, France|H?pital LAPEYRONIE, Montpellier, France|CH E Muller, Mulhouse, France|Hotel Dieu, Nantes, France|Archet 1, Nice, France|CHU Nimes, Nimes, France|H?pital de la Source, Orléans, France|Cochin, Paris, France|Hopital St louis, Paris, France|Necker, Paris, France|Pitie Salpetrière, Paris, France|St Antoine, Paris, France|CH Perpignan, Perpignan, France|H?pital du HAUT LEVEQUE, Pessac, France|Hopital Lyon Sud, Pierre Benite, France|CHU Mileterie, Poitiers, France|Hopital R Debre, Reims, France|H?pital de PONTCHAILLOU, Rennes, France|CH Victor PROVO, Roubaix, France|Centre HENRI BECQUEREL, Rouen, France|Institut de Cancérologie de la Loire, Saint-priest-en-jarez, France|centre rene Huguenin, St Cloud, France|CHU Hautepierre, Strasbourg, France|HIA Ste Anne, Toulon, France|H?pital de PURPAN, Toulouse, France|CHU Tours, Tours, France|Hotel Dieu, Valenciennes, France|CH Brabois, Vandoeuvre Les Nancy, France|IGR, Villejuif, France|St. Johannes-Hospital, Duisburg, Germany|Robert Bosch-Krankenhaus, Stuttgart, Germany|Ospedali Riuniti di Bergamo, Bergamo, Italy|Ospedale San Gerardo, Monza, Italy|Dipartimento Oncologico La Maddalena, Palermo, Italy Less <<
NCT03173612 Acute Myeloid Leukemia UNKNOWN 2025-12-24 InstituteHBDH, Tianjin, Tianji... More >>n, 300020, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.05mL

0.41mL

0.20mL

10.25mL

2.05mL

1.02mL

20.49mL

4.10mL

2.05mL

References

 

Historical Records

Categories